A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ocupress Side Effects, and Drug Interactions - Carteolol
Ocupress Side Effects, and Drug Interactions - Carteolol
SIDE EFFECTS
The following adverse reactions have been reported in clinical
trials with Ocupress Ophthalmic Solution:
Ocular: Transient eye
irritation, burning, tearing, conjunctival hyperemia and edema
occurred in about 1 of 4 patients. Ocular symptoms including blurred
and cloudy vision, photophobia,
decreased night vision, and ptosis
and ocular signs including
blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity
occurred occasionally.
Systemic: As
is characteristic
of nonselective adrenergic blocking agents, Ocupress may cause
bradycardia and
decreased blood pressure
(see WARNINGS). The following
systemic events have occasionally been reported with the use of
Ocupress: cardiac arrhythmia, heart
palpitation, dyspnea,
asthenia, headache,
dizziness, insomnia, sinusitis,
and taste perversion.
The following additional adverse reactions have been reported with
ophthalmic use of beta-1 and beta-2 (nonselective) adrenergic
receptor blocking
agents:
Body As a Whole:
Headache
Cardiovascular: Arrhythmia, syncope,
heart block, cerebral
vascular accident, cerebral ischemia,
congestive heart failure,
palpitation (see WARNINGS).
Digestive: Nausea
Psychiatric: Depression
Skin: Hypersensitivity, including localized
and generalized rash
Respiratory: Bronchospasm (predominantly in patients
with pre-existing bronchospastic disease), respiratory
failure (see WARNINGS)
Endocrine: Masked symptoms of hypoglycemia
in insulin-dependent diabetics (see WARNINGS)
Special Senses: Signs and symptoms of keratitis,
blepharoptosis, visual disturbances including refractive
changes (due to withdrawal
of miotic therapy in
some cases), diplopia,
ptosis.
Other reactions associated with the oral
use of nonselective adrenergic receptor blocking
agents should be considered potential
effects with ophthalmic use of these agents.
DRUG INTERACTIONS
Ocupress should be used with caution in patients who are receiving
a beta-adrenergic blocking
agent orally because of
the potential for
additive effects on systemic
beta-blockade.
Close observation of the patient
is recommended when a beta-blocker is administered to patients receiving
catecholamine-depleting drugs such as reserpine, because of possible
additive effects and
the production of
hypotension and/or marked bradycardia,
which may produce vertigo, syncope, or postural
hypotension.
top
